All In Biotech

NDA 022036 · Currax

Silenor

Doxepin Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Oct 29, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Mar 17, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

19

4 Phase 3, 3 recruiting

FAERS reports

2,564

1,560 serious, 369 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 21, 2026.

1. INDICATIONS AND USAGE SILENOR is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration . SILENOR (doxepin) tablets are indicated for the treatment of insomnia characterized by difficulties with sleep maintenance. ( 1 , 14 )

Mechanism: The mechanism of action of doxepin in sleep maintenance is unclear; however, doxepin's effect could be mediated through antagonism of the H 1 receptor .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • SILENOR · DOXEPIN HYDROCHLORIDE EQ 3MG BASE · TABLET, ORAL · Prescription · TE AB
  • SILENOR · DOXEPIN HYDROCHLORIDE EQ 6MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Doxepin" as an intervention, any sponsor and status, largest first.

All 19 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective278
  • pain228
  • insomnia203
  • fatigue192
  • completed suicide189
  • dizziness186
  • fall183
  • toxicity to various agents168
  • anxiety167
  • headache153
  • off label use145
  • pruritus135

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200420
200536
200643
200715
200813
200924
201026
201125
201246
201352
201419
201555
2016146
2017152
2018126
2019223
2020191
2021194
2022156
2023169
2024261
2025335
2026237

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Silenor (Doxepin HCl)

2024 spending

$504K

Beneficiaries

182

816 claims

Per beneficiary

$2,767

$16.78 per unit

View as table
YearSpending
2020$13,046,161
2021$2,811,616
2022$1,379,343
2023$906,535
2024$503,609

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 310 on PubMed

Sponsor: Currax

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.